India's Bold Step Towards Biopharma Dominance in Budget 2026-27

The Union Budget 2026-27 of India has introduced the Biopharma SHAKTI initiative, a significant move aimed at transforming India into a global hub for biopharmaceuticals. This initiative, with an outlay of Rs. 10,000 crores over five years, is designed to boost domestic production and development of biologics and biosimilars, enhance clinical research capacities, and strengthen regulatory frameworks. Through a comprehensive approach that integrates manufacturing, research, skilled workforce development, and innovation, the program seeks to elevate India's position in the global biopharma industry while ensuring domestic access to affordable biopharmaceuticals.

Source: Original Link

Read more